Related Experiment Videos
Left atrial thrombi despite anticoagulant and antiplatelet therapy
Insights
Patients with left atrial thrombi face a high risk of arterial embolization, especially when spontaneous echo contrast is present. Medical therapy can reduce thrombus size, but embolization risk remains significant.
Area of Science:
- Cardiology
- Vascular Medicine
- Diagnostic Imaging
Background:
- Left atrial thrombi are a known risk factor for arterial embolization.
- Understanding risk factors and thrombus development is crucial for patient management.
Purpose of the Study:
- To investigate risk factors for embolization in patients with left atrial thrombi.
- To evaluate thrombus development and resolution under medical therapy.
Main Methods:
- Prospective study of 29 patients with echocardiographically detected left atrial thrombi.
- Transesophageal and transthoracic echocardiography performed at two time points over 18 months.
- Comparison of patients with and without a history of arterial embolization, analyzing clinical and echocardiographic parameters.
Main Results:
- Spontaneous echo contrast in the left atrium was significantly associated with thromboembolism (p = 0.038).
- Arterial embolism occurred in 14% per patient per year, even with anticoagulant or antiplatelet therapy.
- Medical therapy led to thrombus resolution in 12 patients, with a higher detection rate of residual thrombi in patients treated with phenprocoumon compared to aspirin or no treatment.
Conclusions:
- Left atrial thrombi pose a high risk of arterial embolization, irrespective of standard anticoagulant or antiplatelet treatment.
- Spontaneous echo contrast is a key predictor of embolization events.
- Antiplatelet and anticoagulative agents can facilitate thrombus reduction in size.
Abstract:
To investigate risk factors for embolization in patients with echocardiographically detected left atrial thrombi and to evaluate thrombus development, we examined 29 patients with transesophageal and transthoracic echocardiography at two points during a follow-up of 18 months. We compared patients with a history of possible arterial embolization (n = 13) with those without (n = 16) in regard to age, gender, left atrial dilatation, localization of the thrombus in the left atrial cavity, spontaneous echo contrast, and atrial fibrillation. Eight patients were treated with aspirin, 20 with phenprocoumon. Only left atrial spontaneous contrast was associated with thromboembolism (10/15 patients with spontaneous contrast experienced arterial embolism; p = 0.038). In six patients arterial embolism occurred after thrombus detection (14% per patient per year). Four of these patients were treated with phenprocoumon, two with aspirin. At reexamination, one thrombus was detected in the patient without anticoagulant treatment and one thrombus was detected in the 8 patients treated with aspirin (13%), compared with ten thrombi detected in the 20 patients (50%) treated with phenprocoumon (p = NS). In 17 patients no thrombus was seen at reexamination. Since only 2 patients had undergone thrombectomy and 3 experienced arterial embolism during follow-up, thrombi disappeared under medical therapy in 12 patients. Patients with left atrial thrombi have a high risk of arterial embolization despite proper anticoagulative or antiplatelet treatment. Embolization occurs significantly more often if spontaneous echo contrast can be visualized. Left atrial thrombi can be reduced in size by the administration of antiplatelet and anticoagulative agents.(ABSTRACT TRUNCATED AT 250 WORDS)